Moxifloxacin Tillomed 400 mg film coated tablets

DRUG3 trials

Sponsors

Leiden University Medical Center, Aalborg University Hospital, Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Conditions

Bacilliferous pulmonary tuberculosisBrain abscessprosthetic joint infection

Phase 2

RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BASED ON HIGH DOSE RIFAMPICIN, HIGH DOSE MOXIFLOXACIN AND LINEZOLID IN PATIENTS WITH BACILLIFEROUS PULMONARY TUBERCULOSIS (RML-TB).

CompletedCTIS2023-509075-17-00

Fundacio Hospital Universitari Vall D’Hebron Institut De RecercaBacilliferous pulmonary tuberculosis

Start: 2024-01-17End: 2025-04-10Target: 120Updated: 2025-06-27

Phase 4

Rifampicin Combination Therapy versus Targeted Antimicrobial Monotherapy in the Oral Antimicrobial Treatment Phase of Staphylococcal Prosthetic Joint Infection

RecruitingCTIS2022-501620-26-00

Leiden University Medical Centerprosthetic joint infection

Start: 2023-05-15Target: 316Updated: 2025-07-07

Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL)

RecruitingCTIS2023-505483-11-00

Aalborg University HospitalBrain abscess

Start: 2021-05-02Target: 370Updated: 2025-02-27

Related Papers

Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol.

2025-12-07

RIFAMPICIN COMBINATION THERAPY VERSUS TARGETED ANTIMICROBIAL MONOTHERAPY IN THE ORAL ANTIMICROBIAL TREATMENT PHASE OF STAPHYLOCOCCAL PROSTHETIC JOINT INFECTION (RICOTTA-TRIAL): PROTOCOL FOR A RANDOMIZED, CONTROLLED, OPEN-LABEL, NON-INFERIORITY TRIAL

Orthopaedic Proceedings2024-11-221 citations